Sarilumab

#	Item
1	Sarilumab for moderate to severe active rheumatoid arthritis Add to Reading List Source URL: www.hsc.nihr.ac.uk Language: English
2	May 21, 2015 Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis Includes study in patients who were inadequate responders to or intolerant of Add to Reading List Source URL: files.shareholder.com Language: English Medicine Immunosuppressants Monoclonal antibodies Regeneron Rheumatoid arthritis Sarilumab Biologic Pharmaceutical industry Clinical trial Pharmacology Pharmaceutical sciences Health
3	PRESS RELEASE Sanofi and Regeneron Announce New, Detailed Data from Positive Sarilumab Phase 3 Rheumatoid Arthritis Trial at EULAR - Both doses of investigational drug sarilumab met all three co-primary endpoints - New Add to Reading List Source URL: en.sanofi.com Language: English - Date: 2014-06-12 01:00:21 Pharmacology Science Arthritis Rheumatoid arthritis Placebo Regeneron Clinical trial Health Medicine Clinical research
4	A Breakthrough Year 2012 Annual Report Add to Reading List Source URL: files.shareholder.com Language: English Pharmacology Monoclonal antibodies Regeneron Aflibercept Sarilumab Biologic Bevacizumab Vascular endothelial growth factor Biopharmaceutical Biology Medicine Biotechnology